Skip to main content

IMRX

Stock
Health Care
Biotechnology

Performance overview

IMRX Price
Price Chart

Forward-looking statistics

Beta
0.82
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees68
Market cap$40.6M

Fundamentals

Enterprise value$89.5M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity9.76

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.97
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$7M
Put-call ratio—

Macro factor sensitivity

Growth-2.6
Credit+10.9
Liquidity+3.8
Inflation-8.1
Commodities-2.4
Interest Rates-2.7

Valuation

Dividend yield0.00%
PEG Ratio-2.10
Price to sales—
P/E Ratio-2.10
Enterprise Value to Revenue—
Price to book2.97

Upcoming events

Next earnings dayMay 8, 2024
Next dividend day—
Ex. dividend day—

News

Why Is Immuneering Stock Trading Higher On Tuesday?

On Tuesday, Immuneering Corporation IMRX revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms.

Benzinga (January 7, 2025)
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.

Zacks Investment Research (October 16, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free